Immunovant Could Potentially Be An M&A Target, Writes Analyst
Cantor Fitzgerald initiated coverage on Immunovant Inc (NASDAQ:IMVT) with an Overweight rating and a price target of $30. The company’s pipeline includes…
Guggenheim Upgrades Immunovant to Buy
Guggenheim analyst Yatin Suneja upgrades Immunovant (NASDAQ:IMVT) from Neutral to Buy.
Analyst Expectations for Immunovant’s Future
Immunovant (NASDAQ:IMVT) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish…
Universal Health Services, Madrigal Pharmaceuticals And These Overbought Majors In The Healthcare Sector
The most overbought stocks in the healthcare sector presents an opportunity to go short on these overvalued companies.
What 6 Analyst Ratings Have To Say About Immunovant
Within the last quarter, Immunovant (NASDAQ:IMVT) has observed the following analyst ratings:
6 Analysts Have This to Say About Immunovant
Over the past 3 months, 6 analysts have published their opinion on Immunovant (NASDAQ:IMVT) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
Where Immunovant Stands With Analysts
Immunovant (NASDAQ:IMVT) has observed the following analyst ratings within the last quarter:
HC Wainwright & Co. Maintains Buy on Immunovant, Raises Price Target to $17
HC Wainwright & Co. analyst Douglas Tsao maintains Immunovant (NASDAQ:IMVT) with a Buy and raises the price target from $16 to $17.
SVB Leerink Maintains Outperform on Immunovant, Raises Price Target to $14
SVB Leerink analyst Mike Kratky maintains Immunovant (NASDAQ:IMVT) with a Outperform and raises the price target from $12 to $14.
Immunovant: Q2 Earnings Insights
Immunovant (NASDAQ:IMVT) reported its Q2 earnings results on Friday, November 4, 2022 at 07:00 AM.
Here's what investors need to know about the announcement.